MMED Stock Forecast & Price Target

Minimed Group is a leading diabetes technology company with a wide range of innovative solutions and a strong track record of regulatory clearances and revenue growth. Despite facing competition and pricing challenges, the company's strong pipeline and partnerships position it for continued success in the global market. The writer recommends buying MMED shares with a target price of $25, given their strong profitability profile and recurring revenue model, as well as the launch of new devices and pending regulatory approvals for a closed loop algorithm.

Minimed Group is a scaled medical technology company that specializes in diabetes management solutions, including Automated Insulin Delivery Systems and Smart Multiple Daily Injection Systems. However, there are a few key factors that may contribute to the negative outlook on the company's stock. First, MiniMed faces stiff competition in the CGM and insulin delivery space, and the company may struggle to maintain its market share in the face of competition from other companies such as Beta Bionics, Insulet, and Tandem Diabetes Care. Second, there is a risk that payors may limit reimbursement or negotiate for tighter discounts as these diabetes management technologies become more widely adopted. This could lead to lower margins for the company. Third, MiniMed's innovation pipeline, including the development of a next-generation tubed pump, patch pump, and fully-closed loop algorithm, may face regulatory delays, and there is uncertainty around the company's ability to execute on these initiatives. Furthermore, the company's revenue is heavily reliant on recurring sales of CGMs and consumables, which account for about 80% of total revenue in FY26E. This could be a risk if there is a decline in demand for these products. Overall, these factors may contribute to a negative outlook on Minimed Group's stock, and it may face challenges